Unlocking the Potential of Cell & Gene Therapies MasterClass

Online MasterClass | 23 & 24 September, 2021

Nowadays, for as much as 95% of the 7 000 to 10 000 rare diseases that exist, there are no approved therapies. Of the estimated 400 M people worldwide afflicted with a rare disease, 50% are children. Cell and gene therapies have emerged as a new treatment paradigm for many rare diseases. These novel medicines have the potential to provide long-term therapeutic benefits for patients, however their development is both risky and cost intensive. As of the end of 2020, there were 1220 ongoing regenerative medicine and advanced therapy clinical trials and 1085 gene- and cell-based therapeutics companies working worldwide to develop therapies. These companies raised a cumulative amount of $19.9 B in 2020, a two times increase from $9.8 B in 2019. The number of investigational new cell and gene therapy drug applications has tripled in the last three years. Obtaining better insights into the specific technological, clinical and commercial challenges is crucial to ensure advances of this emerging field. Implementation of innovative clinical research methodologies, current and future focused pricing models and ‘up-to-date’ regulatory approval paths constitute interlocked parts towards long term value creation of these novel, curative therapies. Assessing innovative business models and partnerships will enable acceleration of commercialization processes and guarantee timely patients’ access.

THE EVENT WILL START IN
EVENT INTRODUCTION

Nowadays, for as much as 95% of the 7 000 to 10 000 rare diseases that exist, there are no approved therapies. Of the estimated 400 M people worldwide afflicted with a rare disease, 50% are children. Cell and gene therapies have emerged as a new treatment paradigm for many rare diseases. These novel medicines have the potential to provide long-term therapeutic benefits for patients, however their development is both risky and cost intensive. As of the end of 2020, there were 1220 ongoing regenerative medicine and advanced therapy clinical trials and 1085 gene- and cell-based therapeutics companies working worldwide to develop therapies. These companies raised a cumulative amount of $19.9 B in 2020, a two times increase from $9.8 B in 2019. The number of investigational new cell and gene therapy drug applications has tripled in the last three years. Obtaining better insights into the specific technological, clinical and commercial challenges is crucial to ensure advances of this emerging field. Implementation of innovative clinical research methodologies, current and future focused pricing models and ‘up-to-date’ regulatory approval paths constitute interlocked parts towards long term value creation of these novel, curative therapies. Assessing innovative business models and partnerships will enable acceleration of commercialization processes and guarantee timely patients’ access.

Who should attend?

  • Pharmaceutical/Biotech leaders
  • Senior business developers
  • Portfolio managers
  • R&D heads
  • Directors of regulatory affairs
  • Strategic program directors
  • Global innovation leaders
  • Commercial managers
  • Strategic program developers
  • Pharmaceutical executives

REQUEST AGENDA FORM
DOWNLOAD THE AGENDA
Unlocking the Potential of Cell & Gene Therapies MasterClass
Name
Corporate email
Corporate phone
E-mail consent
Privacy Policy

Past Clients

Testimonials

The level of professionalism of the trainer. Fine-tuned program without wasting time

Managing Director – European pharma company

Testimonials

Clear and interesting way of presenting issues, good examples and very knowledgeable trainer.

HR Director - Multinational company based in Europe

Testimonials

Excellent trainer, super skilled, funny and extremely dynamic

M&A Professional

Testimonials

This training was interesting and I would love to attend more trainings like this.

HR Professional

Testimonials

All lectures of the trainer was exactly what I was looking for and it was directly related to my experties and area that I am working. On top of that he prepared all lectures in a very practical way and also took his time to asnwers to the questions and he made sure that we got the asnwer. The organization of this class was also very good.

Pharmaceutical professional

Testimonials

Comprehensive overview with very knowledgeable and experienced trainers. The break-out sessions were great as they made the course more interactive and allowed us to apply the concepts in practice.

Banking professional from Europe

About GLC EUROPE

Global Leading Conferences is specialized in designing, creating and executing impactful, and pragmatic Conferences, Masterclasses and in-house training.

We take pride in empowering thousands of professionals around the world to learn, network, make connections, and do business with thought leaders and visionaries across multiple industries.

GLC actively collaborates with professionals in major sectors, such as Finance, Pharmaceutical, Human Resources, Health & Safety and Energy to understand the challenges and issues that each industry endures, to be able to construct exclusive and top-tier learning and networking platforms.

Specialized in planning, designing, and organizing interactive, impactful, and pragmatic B2B events, GLC actively collaborates with professionals in major sectors, such as Finance, Pharmaceutical, Human Resources, Health & Safety, and Energy to understand the challenges and issues that each industry endures.

10
years

of constructing industry focused events where business meets intelligence

299
events

where we have been learning to provide a unique experience for our customers

3410
speakers

from top-notch industry establishments proven to make a difference

17761
clients

thereof 96% would attend a GLC event again and would recommend GLC

The MANAGEMENT

GHAZAL ZOHREHNEJAD

Managing Director / Co-founder

LÁSZLÓ ÁRVAI

Managing Director / Co-founder

KRISZTIÁN ÖTVÖS

Managing Director / Co-founder